Table 5.

The Comparison of Severe Adverse Events (≥Grade III) of 173 mCRC Patients Between the Cetuximab Group and Bevacizumab Group

	Cetuximab (N = 98)	Bevacizumab (N = 75)	p Value
Events	25 (25.5%)	20 (26.7%)	0.658
Neutropenia	7 (7.1%)	6 (8.0%)
Anemia	4 (4.1%)	6 (8.0%)
Oral mucositis	2 (2.0%)	1 (1.3%)
Diarrhea	0 (0.0%)	2 (2.6%)
Paresthesia	3 (3.1%)	0 (0.0%)
Nausea/vomiting	4 (4.1%)	3 (4.0%)
Liver function impairment	1 (1.0%)	2 (2.6%)
Renal function impairment	3 (3.1%)	0 (0.0%)
Alopecia	1 (1.0%)	0 (0.0%)

All mCRC patients with wild-type RAS gene.